Cargando…

Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study

The incidence of factor IX (FIX) inhibitors in severe hemophilia B (SHB) is not well defined. Frequencies of 3-5% have been reported but most studies to date have been small, including patients with different severities, and without prospective follow up for inhibitor incidence. The study objective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Male, Christoph, Andersson, Nadine G, Rafowicz, Anne, Liesner, Ri, Kurnik, Karin, Fischer, Kathelijn, Platokouki, Helen, Santagostino, Elena, Chambost, Hervé, Nolan, Beatrice, Königs, Christoph, Kenet, Gili, Ljung, Rolf, van den Berg, H. Marijke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776246/ https://www.ncbi.nlm.nih.gov/pubmed/31919092 http://dx.doi.org/10.3324/haematol.2019.239160

Ejemplares similares

Novel F8 and F9 gene variants from the PedNet hemophilia registry classified according to ACMG/AMP guidelines
por: Andersson, Nadine G., et al.
Publicado: (2020)

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
por: Male, Christoph, et al.
Publicado: (2022)

F8/F9 variants in the population-based PedNet Registry cohort compared with locus-specific genetic databases of the European Association for Haemophilia and Allied Disorders and the Centers for Disease Control and Prevention Hemophilia A or Hemophilia B Mutation Project
por: Labarque, Veerle, et al.
Publicado: (2023)

Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds
por: Andersson, Nadine G., et al.
Publicado: (2019)

BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial
por: Ljung, Rolf, et al.
Publicado: (2023)

Considerations for shared decision management in previously untreated patients with hemophilia A or B
por: Astermark, Jan, et al.
Publicado: (2023)

Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children: Results of a Phase 3 Trial
por: Kenet, Gili, et al.
Publicado: (2016)

Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study
por: Halimeh, Susan, et al.
Publicado: (2013)

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
por: Königs, Christoph, et al.
Publicado: (2022)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Thrombin generation and implications for hemophilia therapies: A narrative review
por: Sidonio, Robert F., et al.
Publicado: (2022)

Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
por: Shapiro, Amy D., et al.
Publicado: (2023)

Principles of care for acquired hemophilia
por: Dolan, Gerry, et al.
Publicado: (2021)

Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature
por: Lalezari, Shadan, et al.
Publicado: (2021)

Desmopressin in moderate hemophilia A patients: a treatment worth considering
por: Loomans, Janneke I., et al.
Publicado: (2018)

Prognosis of CRT-treated and CRT-untreated unselected population with LBBB in Stockholm County
por: Gatti, Paolo, et al.
Publicado: (2023)

Aspects of prophylactic treatment of hemophilia
por: Ljung, Rolf
Publicado: (2016)

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2021)

Long‐term safety and efficacy of N8‐GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5
por: Šaulytė Trakymienė, Sonata, et al.
Publicado: (2020)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

Prevention and Management of Bleeding Episodes in Children with Hemophilia
por: Ljung, Rolf C. R.
Publicado: (2018)

Validation of the pedHAL(short) and HAL(short) in Dutch children and adults with haemophilia
por: Kuijlaars, Isolde A. R., et al.
Publicado: (2022)

Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses
por: Dardik, Rima, et al.
Publicado: (2021)

Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions
por: Dardik, Rima, et al.
Publicado: (2023)

Efficacy and Safety of Fingolimod in an Unselected Patient Population
por: Rasenack, Maria, et al.
Publicado: (2016)

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Shortening the paediatric Haemophilia Activities List (pedHAL) based on pooled data from international studies
por: Kuijlaars, Isolde A. R., et al.
Publicado: (2021)

The Paediatric Haemophilia Activities List (pedHAL) in routine assessment: changes over time, child‐parent agreement and informative domains
por: Kuijlaars, Isolde A. R., et al.
Publicado: (2019)

The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis
por: Frappaz, D, et al.
Publicado: (2002)

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
por: Négrier, Claude, et al.
Publicado: (2022)

Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A
por: Schep, Sarah J., et al.
Publicado: (2021)

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
por: Carcao, Manuel, et al.
Publicado: (2019)

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
por: Colombo, Giorgio L, et al.
Publicado: (2011)

Infrared Thermography as a Non-Invasive Tool to Explore Differences in the Musculoskeletal System of Children with Hemophilia Compared to an Age-Matched Healthy Group
por: Seuser, Axel, et al.
Publicado: (2018)

Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators
por: Karim, Ahmad Faisal, et al.
Publicado: (2020)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Virtual Med-Peds: Description of the First Virtual Med-Peds Student Elective During COVID-19
por: Divatia, Himani, et al.
Publicado: (2020)

Diabetes prevalence and metabolic risk profile in an unselected population visiting pharmacies in Switzerland
por: Rey, Alexandre, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_pa3bv2viicc33igor1a9jhuedg